---
title: '''Home inspections'' for life sciences companies going public before clinical
  proof-of-concept'
date: '2024-12-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39716718/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241224170756&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: For the period from 2010 to 2021, we have observed a phenomenon of life
  sciences companies conducting Initial Public Offerings (IPOs) without any assets
  that have demonstrated clinical proof-of-concept (POC). Ideally, this area of investment
  is targeted by investors with the knowledge and resources to assess the probability
  of success of such early-stage programs based upon adequately planned and performed
  due diligence. Our analysis of this trend calls for the establishment of a ...
disable_comments: true
---
For the period from 2010 to 2021, we have observed a phenomenon of life sciences companies conducting Initial Public Offerings (IPOs) without any assets that have demonstrated clinical proof-of-concept (POC). Ideally, this area of investment is targeted by investors with the knowledge and resources to assess the probability of success of such early-stage programs based upon adequately planned and performed due diligence. Our analysis of this trend calls for the establishment of a ...